Ildus Ya. Lutfullin
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Ildus Ya. Lutfullin has a total of 49 co-authors. Here are the top co-authors by number of shared publications:
- Asiya I. Safina
Kazan State Medical Academy
5 shared publications - Maria A. Daminova
Russian Medical Academy of Continuous Professional Education
5 shared publications - I. I. Zakirov
Kazan State Medical Academy
3 shared publications - O. V. Sharipova
City Children’s Hospital No. 1
2 shared publications - V. S. Filatov
Department of Health in Kazan of the Ministry of Health of the Republic of Tatarstan
2 shared publications - A. M. Agliullina
Medical Center “Family Clinic
1 shared publication
Latest Publications
- Open Access
- 5 April 2025
- Published by Remedium, Ltd. in Meditsinskiy sovet = Medical Council
- No. 1,p. 238-245
The problem of late diagnosis of Kawasaki disease: description of a series of 19 cases
Introduction. Kawasaki disease (KD) is the most common cause of acquired heart disease in children. Diagnosis of CD is based on the clinical manifestations of the disease, however, a number of its features and low awareness of doctors can make diagnosis difficult.Aim. To study epidemiological indicators, patient routing and clinical and laboratory features of the course of Kawasaki disease in children hospitalized at the City Children’s Hospital No. 1 of Kazan with this diagnosis in the period 2015–2022.Materials and methods. An empirical description of a patient case series was conducted on a group of 19 children hospitalized with a diagnosis of full-blown CD.Results and discussion. Late periods of diagnosis were identified (14.4 ± 7.3 days) and administration of intravenous immunoglobulin at a dose of 2 g/kg body weight (16.1 ± 7.9 days, the mode of the indicator was the 13th day), as well as a large percentage detection of coronary anomalies in the study group (68%, n = 13) and residual coronary anomalies at discharge (32%, n = 6). The referral diagnosis was correct only in 21% of cases; most often, the diagnosis of an infectious disease was made at the prehospital stage and in 79% of cases antimicrobial drugs were prescribed. At the prehospital stage, patients were diagnosed with rash syndrome (84%), changes in the oral mucosa (74%) and conjunctivitis (63%). Laboratory abnormalities in all patients before hospitalization were typical for Kawasaki disease: accelerated erythrocyte sedimentation rate (41.4 ± 14.3 mm/ hour), increased C-reactive protein (98.2 ± 47.6 mg/l), leukocytosis (23.0 ± 8.4 x 109/l), decreased hemoglobin (100.0 ± 8.9 g/l) and thrombocytosis (630.6 ± 215.5 x 109/l).Conclusions. The study included only children with the full form of CD; therefore, the most likely reason for the late diagnosis is the low level of awareness of the disease criteria among non-rheumatological doctors. It is required to conduct educational activities among pediatricians, infectious disease specialists, and general practitioners to increase alertness for the purpose of early diagnosis of CD.
- 5 April 2025
- Published by Remedium, Ltd. in Meditsinskiy sovet = Medical Council
- No. 1,p. 238-245
Open AccessThe problem of late diagnosis of Kawasaki disease: description of a series of 19 cases
Introduction. Kawasaki disease (KD) is the most common cause of acquired heart disease in children. Diagnosis of CD is based on the clinical manifestations of the disease, however, a number of its features and low awareness of doctors can make diagnosis difficult.Aim. To study epidemiological indicators, patient routing and clinical and laboratory features of the course of Kawasaki disease in children hospitalized at the City Children’s Hospital No. 1 of Kazan with this diagnosis in the period 2015–2022.Materials and methods. An empirical description of a patient case series was conducted on a group of 19 children hospitalized with a diagnosis of full-blown CD.Results and discussion. Late periods of diagnosis were identified (14.4 ± 7.3 days) and administration of intravenous immunoglobulin at a dose of 2 g/kg body weight (16.1 ± 7.9 days, the mode of the indicator was the 13th day), as well as a large percentage detection of coronary anomalies in the study group (68%, n = 13) and residual coronary anomalies at discharge (32%, n = 6). The referral diagnosis was correct only in 21% of cases; most often, the diagnosis of an infectious disease was made at the prehospital stage and in 79% of cases antimicrobial drugs were prescribed. At the prehospital stage, patients were diagnosed with rash syndrome (84%), changes in the oral mucosa (74%) and conjunctivitis (63%). Laboratory abnormalities in all patients before hospitalization were typical for Kawasaki disease: accelerated erythrocyte sedimentation rate (41.4 ± 14.3 mm/ hour), increased C-reactive protein (98.2 ± 47.6 mg/l), leukocytosis (23.0 ± 8.4 x 109/l), decreased hemoglobin (100.0 ± 8.9 g/l) and thrombocytosis (630.6 ± 215.5 x 109/l).Conclusions. The study included only children with the full form of CD; therefore, the most likely reason for the late diagnosis is the low level of awareness of the disease criteria among non-rheumatological doctors. It is required to conduct educational activities among pediatricians, infectious disease specialists, and general practitioners to increase alertness for the purpose of early diagnosis of CD.
- 18 November 2022
- Published by The National Academy of Pediatric Science and Innovation in Rossiyskiy Vestnik Perinatologii i Pediatrii (Russian Bulletin of Perinatology and Pediatrics)
- Vol. 67 (5) , 130-134
Management of arterial hypertension: practical aspects in young athletes
Regular physical activity has a positive effect on blood pressure, but despite this fact, arterial hypertension in athletes, including children and adolescents, is a common problem. It is known that an increase in blood pressure is the most common cardiac symptom detected on pre-competition examination or physical performance testing. The risk factors for hypertension in young athletes are generally similar to those in the child and adolescent population as a whole, but some risk factors exist that are specific to athletes. The article discusses the possibilities of admittance of young athletes to sports competitions and the main aspects of drug and non-drug therapy.
- 18 November 2022
- Published by The National Academy of Pediatric Science and Innovation in Rossiyskiy Vestnik Perinatologii i Pediatrii (Russian Bulletin of Perinatology and Pediatrics)
- Vol. 67 (5) , 130-134
Management of arterial hypertension: practical aspects in young athletes
Regular physical activity has a positive effect on blood pressure, but despite this fact, arterial hypertension in athletes, including children and adolescents, is a common problem. It is known that an increase in blood pressure is the most common cardiac symptom detected on pre-competition examination or physical performance testing. The risk factors for hypertension in young athletes are generally similar to those in the child and adolescent population as a whole, but some risk factors exist that are specific to athletes. The article discusses the possibilities of admittance of young athletes to sports competitions and the main aspects of drug and non-drug therapy.
- Open Access
- 16 November 2022
- Published by Remedium, Ltd. in Meditsinskiy sovet = Medical Council
- No. 19,p. 153-161
Experience of organizing a children’s COVID and provisory hospital on the basis of children’s city hospital No1 in Kazan
Introduction. The pandemic of coronavirus infection, declared by WHO on March 11, 2020, in the first months practically did not affect the inhabitants of the Russian Federation, which gave the healthcare system an advantage in the form of a temporary lag to prepare for the mass admission of patients to infectious diseases hospitals.Aim. To disclose the issues of organization and operation of a children’s covid and provisional hospital on the basis of a separate medical institution as a single whole entity, which functioned for 495 days from 04/08/2020 to 08/15/2021 on the basis of the City Children’s Hospital №1 of Kazan.Materials and methods. Descriptive statistics of 1554 cases of coronavirus infection COVID-19 in childhood are given, topical aspects of epidemiology, the clinical course of the disease and the significance of comorbid pathology are discussed.Results. In the process of work, we noted three rises in the incidence: in June 2020, December 2020 and July 2021. In 61.2% (n = 951) of cases, intrafamily infection was noted, in 11.9% (n = 185) – infection in children’s groups, in 26.9% (n = 418) of cases the source of infection was not identified. The course of the disease was moderate in 74.3% of patients (1154 children), severe in 4.1% (64 children) and mild in 21.6% (336 children), whose hospitalization was justified by social reasons or serious comorbid pathology. The incidence of pneumonia was 21.4% (333 children). COVID-19 was diagnosed in 47 newborns, which proceeded in a severe (2.1% of cases, n = 1), moderate (66% of cases, n = 31) and mild (31.9% of cases, n = 15) form.Conclusions. City Children’s Hospital № 1 of Kazan, transformed into a temporary children’s covid and provisional hospital, provided medical care to 7831 children, including 1554 patients with COVID-19 in the period from 04/08/2020 to 08/15/2021. This organizational decision made it possible to provide those in need with the necessary medical care, organize the routing of patients, and create a reserve of beds.
- 16 November 2022
- Published by Remedium, Ltd. in Meditsinskiy sovet = Medical Council
- No. 19,p. 153-161
Open AccessExperience of organizing a children’s COVID and provisory hospital on the basis of children’s city hospital No1 in Kazan
Introduction. The pandemic of coronavirus infection, declared by WHO on March 11, 2020, in the first months practically did not affect the inhabitants of the Russian Federation, which gave the healthcare system an advantage in the form of a temporary lag to prepare for the mass admission of patients to infectious diseases hospitals.Aim. To disclose the issues of organization and operation of a children’s covid and provisional hospital on the basis of a separate medical institution as a single whole entity, which functioned for 495 days from 04/08/2020 to 08/15/2021 on the basis of the City Children’s Hospital №1 of Kazan.Materials and methods. Descriptive statistics of 1554 cases of coronavirus infection COVID-19 in childhood are given, topical aspects of epidemiology, the clinical course of the disease and the significance of comorbid pathology are discussed.Results. In the process of work, we noted three rises in the incidence: in June 2020, December 2020 and July 2021. In 61.2% (n = 951) of cases, intrafamily infection was noted, in 11.9% (n = 185) – infection in children’s groups, in 26.9% (n = 418) of cases the source of infection was not identified. The course of the disease was moderate in 74.3% of patients (1154 children), severe in 4.1% (64 children) and mild in 21.6% (336 children), whose hospitalization was justified by social reasons or serious comorbid pathology. The incidence of pneumonia was 21.4% (333 children). COVID-19 was diagnosed in 47 newborns, which proceeded in a severe (2.1% of cases, n = 1), moderate (66% of cases, n = 31) and mild (31.9% of cases, n = 15) form.Conclusions. City Children’s Hospital № 1 of Kazan, transformed into a temporary children’s covid and provisional hospital, provided medical care to 7831 children, including 1554 patients with COVID-19 in the period from 04/08/2020 to 08/15/2021. This organizational decision made it possible to provide those in need with the necessary medical care, organize the routing of patients, and create a reserve of beds.
- Open Access
- 21 March 2021
- Published by Remedium, Ltd. in Meditsinskiy sovet = Medical Council
- No. 1,p. 59-65
Modern opportunities of interferons in treatment of children with COVID-19
Introduction. In 2020, most doctors were at the frontlines in the fight against the novel coronavirus infection (COVID-19). In the process of searching for effective etiotropic drugs, news came in that type I interferons had been successfully used for the treatment of COVID-19. Choosing the optimal COVID-19 treatment strategy is of pivotal importance for vulnerable populations such as children.Objective of the study. To show our own experience in providing medical care to children with COVID-19 and present the results of a comparative study of the efficacy and safety of interferon alfa-2b drugs combined with highly active antioxidants in the complex COVID-19 therapy in children.Materials and methods. A comparative study of the efficacy and safety of interferon alfa-2b drugs combined with highly active antioxidants in the complex COVID-19 therapy in children was conducted. The study included children with a laboratoryconfirmed diagnosis of COVID-19 aged 1 – 17 years (n = 85). In the treatment group (n = 45), children received interferon alfa-2b drugs such as VIFERON® rectal suppositories and VIFERON® gel for topical administration according to the dosage regimen and standard therapy. In the control group (n = 40), children only received standard therapy in accordance with the recommendations of the Ministry of Health of Russia.Results and discussion. 3,696 patients, including 3,507 children, received medical care in the City Children’s Hospital No. 1 in Kazan since April 2020. The share of laboratory-confirmed COVID-19 cases among admitted children was 21% (n = 736), of which 85 were enrolled in the study to assess the efficacy of complex therapy with interferon alpha-2b drugs combined with highly active antioxidants. The interferon alfa-2b therapy of COVID-19 children reduced the duration of the key clinical symptoms of the disease by 1.5-4 days and the virus elimination time by 6 days.Conclusions. The use of interferon alfa-2b VIFERON® rectal suppositories and VIFERON® gel for topical administration according to the dose regimen in combination with the standard therapy in COVID-19 children contributed to faster elimination of clinical symptoms of the disease and virus elimination compared to the standard therapy.
- 21 March 2021
- Published by Remedium, Ltd. in Meditsinskiy sovet = Medical Council
- No. 1,p. 59-65
Open AccessModern opportunities of interferons in treatment of children with COVID-19
Introduction. In 2020, most doctors were at the frontlines in the fight against the novel coronavirus infection (COVID-19). In the process of searching for effective etiotropic drugs, news came in that type I interferons had been successfully used for the treatment of COVID-19. Choosing the optimal COVID-19 treatment strategy is of pivotal importance for vulnerable populations such as children.Objective of the study. To show our own experience in providing medical care to children with COVID-19 and present the results of a comparative study of the efficacy and safety of interferon alfa-2b drugs combined with highly active antioxidants in the complex COVID-19 therapy in children.Materials and methods. A comparative study of the efficacy and safety of interferon alfa-2b drugs combined with highly active antioxidants in the complex COVID-19 therapy in children was conducted. The study included children with a laboratoryconfirmed diagnosis of COVID-19 aged 1 – 17 years (n = 85). In the treatment group (n = 45), children received interferon alfa-2b drugs such as VIFERON® rectal suppositories and VIFERON® gel for topical administration according to the dosage regimen and standard therapy. In the control group (n = 40), children only received standard therapy in accordance with the recommendations of the Ministry of Health of Russia.Results and discussion. 3,696 patients, including 3,507 children, received medical care in the City Children’s Hospital No. 1 in Kazan since April 2020. The share of laboratory-confirmed COVID-19 cases among admitted children was 21% (n = 736), of which 85 were enrolled in the study to assess the efficacy of complex therapy with interferon alpha-2b drugs combined with highly active antioxidants. The interferon alfa-2b therapy of COVID-19 children reduced the duration of the key clinical symptoms of the disease by 1.5-4 days and the virus elimination time by 6 days.Conclusions. The use of interferon alfa-2b VIFERON® rectal suppositories and VIFERON® gel for topical administration according to the dose regimen in combination with the standard therapy in COVID-19 children contributed to faster elimination of clinical symptoms of the disease and virus elimination compared to the standard therapy.
- Open Access
- 22 November 2020
- Published by The National Academy of Pediatric Science and Innovation in Rossiyskiy Vestnik Perinatologii i Pediatrii (Russian Bulletin of Perinatology and Pediatrics)
- Vol. 65 (5) , 245-255
To the 100th anniversary of postgraduate pediatric education at the Kazan State Medical Academy (historical essay)
К 100-летию постдипломного образования педиатров в Казанской государственной медицинской академии (исторический очерк)
- 22 November 2020
- Published by The National Academy of Pediatric Science and Innovation in Rossiyskiy Vestnik Perinatologii i Pediatrii (Russian Bulletin of Perinatology and Pediatrics)
- Vol. 65 (5) , 245-255
Open AccessTo the 100th anniversary of postgraduate pediatric education at the Kazan State Medical Academy (historical essay)
К 100-летию постдипломного образования педиатров в Казанской государственной медицинской академии (исторический очерк)
- Open Access
- 22 November 2020
- Published by The National Academy of Pediatric Science and Innovation in Rossiyskiy Vestnik Perinatologii i Pediatrii (Russian Bulletin of Perinatology and Pediatrics)
- Vol. 65 (5) , 193-197
COVID-19 in children: the accumulated experience?
COVID-19 в детском возрасте: о чем говорит накопленный опыт?
- 22 November 2020
- Published by The National Academy of Pediatric Science and Innovation in Rossiyskiy Vestnik Perinatologii i Pediatrii (Russian Bulletin of Perinatology and Pediatrics)
- Vol. 65 (5) , 193-197
Open AccessCOVID-19 in children: the accumulated experience?
COVID-19 в детском возрасте: о чем говорит накопленный опыт?
- Open Access
- 27 March 2020
- Published by Science for Children Foundation in Pediatric Hematology/Oncology and Immunopathology
- Vol. 19 (1) , 18-26
Use of romiplostim for newly diagnosed immune thrombocytopenia in children
Immune thrombocytopenia (ITP) is a disease with a heterogeneous clinical manifestation. In the majority of children newly diagnosed ITP is a self-limited benign disorder, while chronic ITP develops rarely. The clinical onset of ITP can occur in very different ways: from nearly invisible skin hemorrhage to severe life-threatening bleeding. Conventional treatments promote a response in most patients, but in a small number of children thrombocytopenia is unresponsive. In this article, we describe our experience of the clinical use of romiplostim in children with severe unresponsive newly diagnosed ITP. The study was approved by the Independent Ethics Committee and the Scientific Council of the Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology, and Immunology. The severity of bleeding decreased significantly after the start of romiplostim therapy in all cases. Durable complete (platelets 100 × 109 /l) response was achieved in five out of six patients 4 to 8 weeks after starting therapy. Three children have remained in lasting remission for 1 to 3 years after the discontinuation of romiplostim. There were no adverse events associated with romiplostim.
- 27 March 2020
- Published by Science for Children Foundation in Pediatric Hematology/Oncology and Immunopathology
- Vol. 19 (1) , 18-26
Open AccessUse of romiplostim for newly diagnosed immune thrombocytopenia in children
Immune thrombocytopenia (ITP) is a disease with a heterogeneous clinical manifestation. In the majority of children newly diagnosed ITP is a self-limited benign disorder, while chronic ITP develops rarely. The clinical onset of ITP can occur in very different ways: from nearly invisible skin hemorrhage to severe life-threatening bleeding. Conventional treatments promote a response in most patients, but in a small number of children thrombocytopenia is unresponsive. In this article, we describe our experience of the clinical use of romiplostim in children with severe unresponsive newly diagnosed ITP. The study was approved by the Independent Ethics Committee and the Scientific Council of the Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology, and Immunology. The severity of bleeding decreased significantly after the start of romiplostim therapy in all cases. Durable complete (platelets 100 × 109 /l) response was achieved in five out of six patients 4 to 8 weeks after starting therapy. Three children have remained in lasting remission for 1 to 3 years after the discontinuation of romiplostim. There were no adverse events associated with romiplostim.